"Possible" resistance

Comparison of "possible" HIV resistance results derived from a genotyping report versus the IC50 virtual phenotype

Barbara Bryant, Deborah A. Payne

Research output: Contribution to journalArticle

Abstract

Background: HIV drug-resistance testing employs genotyping, phenotyping, or a hybrid method known as virtual phenotyping. Phenotyping is based on the rate that a drug inhibits viral replication. In genotyping, the virus is sequenced and mutations are analyzed permitting the risk of drug resistance to be designated as "high," "possible," or "none." Virtual phenotyping links sequences of phenotyped isolates to genotype-phenotype pairs in a relational database, thus providing quantitative prediction of drug resistance. This 3-month study correlates "possible" genotypic and virtual phenotypic results. Methods: Genotyping and virtual phenotyping utilized the Viroseq and VitualPhenotype systems, respectively. Results: Of the 267 "possible" resistant genotypic results, 47 were resistant by virtual phenotype (17.6%). Protease inhibitors (PI) had the highest percentage of correlated resistant results (22.6%). Conclusion: "Possible" resistant genotypic results obtained for most of the classes of HIV drugs were eventually classified as "sensitive" by virtual phenotyping. A "possible" resistant genotypic result for PI was more closely correlated to resistance by virtual phenotyping.

Original languageEnglish (US)
Pages (from-to)26-28
Number of pages3
JournalLaboratory Medicine
Volume38
Issue number1
DOIs
StatePublished - 2007

Fingerprint

Drug Resistance
Inhibitory Concentration 50
HIV
Protease Inhibitors
Phenotype
Pharmaceutical Preparations
Genotype
Databases
Viruses
Mutation
Testing

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

@article{cd04391690854495a98695f852b21cff,
title = "{"}Possible{"} resistance: Comparison of {"}possible{"} HIV resistance results derived from a genotyping report versus the IC50 virtual phenotype",
abstract = "Background: HIV drug-resistance testing employs genotyping, phenotyping, or a hybrid method known as virtual phenotyping. Phenotyping is based on the rate that a drug inhibits viral replication. In genotyping, the virus is sequenced and mutations are analyzed permitting the risk of drug resistance to be designated as {"}high,{"} {"}possible,{"} or {"}none.{"} Virtual phenotyping links sequences of phenotyped isolates to genotype-phenotype pairs in a relational database, thus providing quantitative prediction of drug resistance. This 3-month study correlates {"}possible{"} genotypic and virtual phenotypic results. Methods: Genotyping and virtual phenotyping utilized the Viroseq and VitualPhenotype systems, respectively. Results: Of the 267 {"}possible{"} resistant genotypic results, 47 were resistant by virtual phenotype (17.6{\%}). Protease inhibitors (PI) had the highest percentage of correlated resistant results (22.6{\%}). Conclusion: {"}Possible{"} resistant genotypic results obtained for most of the classes of HIV drugs were eventually classified as {"}sensitive{"} by virtual phenotyping. A {"}possible{"} resistant genotypic result for PI was more closely correlated to resistance by virtual phenotyping.",
author = "Barbara Bryant and Payne, {Deborah A.}",
year = "2007",
doi = "10.1309/8X6LLFC1VY3Q3GDB",
language = "English (US)",
volume = "38",
pages = "26--28",
journal = "Laboratory Medicine",
issn = "0007-5027",
publisher = "American Society of Clinical Pathologists",
number = "1",

}

TY - JOUR

T1 - "Possible" resistance

T2 - Comparison of "possible" HIV resistance results derived from a genotyping report versus the IC50 virtual phenotype

AU - Bryant, Barbara

AU - Payne, Deborah A.

PY - 2007

Y1 - 2007

N2 - Background: HIV drug-resistance testing employs genotyping, phenotyping, or a hybrid method known as virtual phenotyping. Phenotyping is based on the rate that a drug inhibits viral replication. In genotyping, the virus is sequenced and mutations are analyzed permitting the risk of drug resistance to be designated as "high," "possible," or "none." Virtual phenotyping links sequences of phenotyped isolates to genotype-phenotype pairs in a relational database, thus providing quantitative prediction of drug resistance. This 3-month study correlates "possible" genotypic and virtual phenotypic results. Methods: Genotyping and virtual phenotyping utilized the Viroseq and VitualPhenotype systems, respectively. Results: Of the 267 "possible" resistant genotypic results, 47 were resistant by virtual phenotype (17.6%). Protease inhibitors (PI) had the highest percentage of correlated resistant results (22.6%). Conclusion: "Possible" resistant genotypic results obtained for most of the classes of HIV drugs were eventually classified as "sensitive" by virtual phenotyping. A "possible" resistant genotypic result for PI was more closely correlated to resistance by virtual phenotyping.

AB - Background: HIV drug-resistance testing employs genotyping, phenotyping, or a hybrid method known as virtual phenotyping. Phenotyping is based on the rate that a drug inhibits viral replication. In genotyping, the virus is sequenced and mutations are analyzed permitting the risk of drug resistance to be designated as "high," "possible," or "none." Virtual phenotyping links sequences of phenotyped isolates to genotype-phenotype pairs in a relational database, thus providing quantitative prediction of drug resistance. This 3-month study correlates "possible" genotypic and virtual phenotypic results. Methods: Genotyping and virtual phenotyping utilized the Viroseq and VitualPhenotype systems, respectively. Results: Of the 267 "possible" resistant genotypic results, 47 were resistant by virtual phenotype (17.6%). Protease inhibitors (PI) had the highest percentage of correlated resistant results (22.6%). Conclusion: "Possible" resistant genotypic results obtained for most of the classes of HIV drugs were eventually classified as "sensitive" by virtual phenotyping. A "possible" resistant genotypic result for PI was more closely correlated to resistance by virtual phenotyping.

UR - http://www.scopus.com/inward/record.url?scp=58149456906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149456906&partnerID=8YFLogxK

U2 - 10.1309/8X6LLFC1VY3Q3GDB

DO - 10.1309/8X6LLFC1VY3Q3GDB

M3 - Article

VL - 38

SP - 26

EP - 28

JO - Laboratory Medicine

JF - Laboratory Medicine

SN - 0007-5027

IS - 1

ER -